Patient Guide: A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 8 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06925542
Status: 🟢 Enrolling Now
Condition: SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Phase: PHASE1

Where You Can Participate

This study is available at 8 locations across the country.

Top locations include:
  • • Redwood City, California
  • • Chicago, Illinois
  • • Iowa City, Iowa
  • • And 5 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease - Join Clinical Trial NCTNCT06925542

How to Join This Clinical Trial - NCTNCT06925542

Learn how to participate in this PHASE1 trial studying an investigational therapy for SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06925542 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 8 locations. Find a study site near you:

Clinical Research Site

Redwood City, California 94063 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Chicago, Illinois 63110 - United States

Status: RECRUITING

Clinical Research Site

Iowa City, Iowa 52242 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Boston, Massachusetts 02118 - United States

Status: RECRUITING

Clinical Research Site

Saint Louis, Missouri 63130 - United States

Status: RECRUITING

Clinical Research Site

Chapel Hill, North Carolina 27599 - United States

Status: RECRUITING

Clinical Research Site

Augsburg, 86156 - Germany

Status: NOT_YET_RECRUITING

Clinical Research Site

Hannover, 30625 - Germany

Status: NOT_YET_RECRUITING

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships